ZeNix: Pretomanid, Bedaquiline, and Varied Doses and Durations of Linezolid in Highly Resistant TB

July 18-21, 2021; Virtual
Reduced doses and/or shorter durations of linezolid are associated with similar efficacy but improved safety.
Format: Microsoft PowerPoint (.ppt)
File Size: 231 KB
Released: July 26, 2021


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Clinical Care Options (CCO) expert insight by Dr Gail Matthews on what to consider when switching suppressed patients with HIV/HBV from oral to long-acting ART regimen

person default Prof Gail Matthews, MD, PhD Released: January 25, 2022

Expert commentary on trends in the management of HABP/VABP from Dr Keith S. Kaye and Clinical Care Options (CCO)

Keith S. Kaye, MD, MPH Released: January 24, 2022

Dr Mark Sulkowski and Clinical Care Options (CCO): Treatment of both HIV and HCV should be prioritized for patients that are coinfected with careful consideration of drug-drug interactions.

Mark S. Sulkowski, MD Released: January 19, 2022

Expert commentary on addressing barriers to vaccine uptake in older individuals, from Dr Barbara Resnick and Clinical Care Options (CCO)

Barbara Resnick, PhD, CRNP Released: January 12, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings